---
figid: PMC9630817__44164_2022_35_Fig7_HTML
pmcid: PMC9630817
image_filename: 44164_2022_35_Fig7_HTML.jpg
figure_link: /pmc/articles/PMC9630817/figure/Fig7/
number: Fig. 7
figure_title: ''
caption: Tested compounds and their in vivo response presented as adverse outcome
  pathway (AOP) for LPS and efficacy outcome pathway (EOP) for the APIs. Starting
  with the molecular initial event (MIE), the binding to the biological target, followed
  by a series of essential biological events, including the measurable key events
  (KE) cytokine release, TEER, Papp and with the adverse outcome (AO)/efficacy outcome
  (EO) that represents the endpoint
article_title: 'Inflammatory bowel disease addressed by Caco-2 and monocyte-derived
  macrophages: an opportunity for an in vitro drug screening assay.'
citation: Sabrina Schnur, et al. 2022;1(4-5):365-383.
year: '2022'

doi: 10.1007/s44164-022-00035-8
journal_title: In vitro models
journal_nlm_ta: ''
publisher_name: Springer International Publishing

keywords:
- Chronic inflammation of GI-tract
- Cell-based co-culture
- IVIVC
- Drug testing
- Efficacy outcome pathways

---
